- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanobiosym Chairman & CEO Dr. Anita Goel, MD, PhD, will present a fresh new vision for American leadership in the coming global nanotechnology revolution to the Senate Subcommittee on Science, Technology and Innovation, chaired by Senator John Kerry (D-Mass.). Dr. Goel, an internationally recognized nanotech expert and a Harvard-MIT trained physicist and physician, will provide testimony at the US Senate hearing on reauthorizing the billion plus-dollar National Nanotechnology Initiative (NNI).
Dr. Goel founded Nanobiosym, Inc. as an innovation engine at the nexus of physics, medicine, and nanotechnology. Her pioneering contributions to the field have been recognized globally by several prestigious honors and awards. Her work at Nanobiosym has been recognized by multiple rounds of competitive funding from the United States Department of Defense agencies, including the Defense Advanced Research Projects Agency (DARPA); the Air Force Office of Scientific Research (AFOSR); the US Department of Energy (DOE) SBIR Programs, and the US Defense Threat Reduction Agency (DTRA).
Nanobiosym, and its commercial partner Nanobiosym Diagnostics, have been privately developing Gene-RADAR®, a portable nanotechnology-enabled platform, that can rapidly and accurately detect genetic fingerprints from any biological organism. The company's vision is to give patients worldwide real-time access to their own diagnostic information via low-cost handheld devices. Dr. Goel will speak about how the US can revitalize its economy by harnessing the global nanotechnology revolution. "Nanotechnology provides a platform for innovation across conventional boundaries of science, technology, and commerce. Furthermore, by its intrinsic multidisciplinary nature, it fosters collaboration across conventional political and economic boundaries. Building on the success of the National Nanotechnology Initiative's first five years, the United States has a historic opportunity to drive nanotechnology to maximize its impact on global challenges, including health, environment, energy, and even building the new global economy," she said.
The hearing scheduled for Thursday, April 24, 2008, is one of the first steps in the reauthorization of the National Nanotechnology Initiative (NNI).
About Nanobiosym Inc.
Nanobiosym Inc., a privately held Massachusetts firm, was founded to develop technologies that integrate advances in physics, biomedicine, and nanotechnology. Nanobiosym Diagnostics, Inc. is the commercial partner of Nanobiosym that focuses on the commercialization of the proprietary Gene Radar® technology platform to empower people worldwide with rapid, accurate, and portable diagnostic information about their own health.
About Dr. Anita Goel
Dr. Anita Goel, Founder, Chairman, & CEO of Nanobiosym, is a Harvard-MIT trained Physicist and Physician who was named in 2005 as one of the world’s “Top 35 science and technology innovators under the age of 35” by MIT’s Technology Review Magazine. In 2006, Dr. Goel received the Global Indus Technovator Award from MIT, an honor recognizing the contributions of top 10 leaders working at the forefront of science, technology, and entrepreneurship. Dr. Goel earned a PhD in Physics from Harvard University, an MD from the Harvard-MIT Joint Division of Health Sciences and Technology (HST), and BS in Physics from Stanford University.
For more information, please click here
NBS Media & Public Relations Dept.
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Graphene under pressure August 26th, 2016
Stretchy supercapacitors power wearable electronics August 25th, 2016
New approach to determining how atoms are arranged in materials August 25th, 2016
Graphene under pressure August 26th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016